BioHive is a biotech company building next-generation human skin biobanks and organoid platforms to transform preclinical research. At the core of its approach, BioHive develops and structures access to diverse, patient-derived skin samples, enabling the generation of in vitro models that capture the full spectrum of human skin biology, including different skin types, ethnic backgrounds, and disease states.

Leveraging this unique biological foundation, BioHive engineers advanced 3D skin organoids that reproduce key structural, cellular, and functional features of human skin. These platforms integrate multiple cell types and disease-relevant components to enable highly predictive studies of efficacy, mechanism of action, biomarker discovery, and safety.

By combining patient-derived biobanks, tissue engineering, multi-omics, and advanced imaging, BioHive delivers translatable, human-relevant data that addresses the limitations of conventional models. Positioned at the forefront of new approach methodologies (NAMs), BioHive supports pharmaceutical and biotech partners in de-risking development, accelerating decision-making, and enabling more precise and effective therapies.

MAbSilico is a premier TechBio company dedicated to developing and providing cutting-edge AI-based solutions for antibody drug design and discovery. They empower biotech and pharmaceutical companies to significantly leverage antibody discovery risks by providing high-potential computational candidates in just a matter of days. These candidates are meticulously designed and characterized in silico and subsequently validated with state-of-the-art biological technologies, ensuring a seamless transition from digital modeling to laboratory success. By combining sophisticated 3D modeling, complex interaction simulations, and advanced linear sequence analysis, MAbSilico defines antibody drug candidates through a rigorous assessment of their epitope, affinity, off-target risk, cross-species reactivity, and developability, ensuring they are fully prepared for biological activity evaluation.

Beyond their services, MAbSilico is advancing its own innovative discovery pipeline available for out-licensing, featuring high-quality leads in monoclonal, bispecific, and antibody-drug conjugate modalities. Their commitment to global innovation is reflected in an aggressive US development strategy, where they are actively seeking strategic partners to extend the deployment of their antibody design platform across the North American ecosystem. This international reach is further strengthened by their exclusive partnership with Yntoab to serve the Korean market and a landmark collaboration with Sartorius. The Sartorius partnership offers a comprehensive end-to-end solution that bridges the gap between lead candidate design and lead candidate production, including integrated cell line development to accelerate the path to clinical trials.

Furthermore, MAbSilico utilizes advanced NLP technologies to gather exhaustive information about antibodies and their targets from global databases, ensuring robust competitive landscape analysis and the freedom to operate for all computationally designed candidates. Through these integrated technologies and global alliances, MAbSilico transforms the traditional discovery process into a predictive, high-velocity engine for the next generation of immunotherapy.

DeepLife is a techbio company advancing drug positioning through artificial intelligence and digital twins of human cell types.

Its platform, TwinCell, simulates cell-type-specific behaviour by integrating over 1 billion harmonized single-cell omics data points with causal AI, enabling more precise target identification, drug repositioning and disease understanding.

DeepLife applies this technology across autoimmune, neurodegenerative and cardio metabolic diseases among others. It partners with pharmaceutical and biotech companies on asset de-risking, indication expansion and disease relevant assessment. The company has established strategic collaborations including with Biersdorf in skin disease and aging.

DeepLife leverages cell-type-specific digital twin models to pinpoint the most relevant disease indications for any therapeutic compound. At the core is TwinCell – a large-scale causal model of cell biology that identifies the molecular drivers of disease and how to reverse them. TwinCell combines this insight with large scale single cell multi omics data to build precise models of human cell types and their regulatory networks.

These digital twins replicate real cellular behaviour, predicting preclinical outcomes and enabling researchers to explore disease mechanisms in silico. This approach uncovers how compounds act at the cell-type level, enhancing target validation, biomarker discovery and indication selection.

Applied across the drug development lifecycle, TwinCell accelerates decision making, reduces risk and improves translational relevance. It supports novel target discovery, asset de-risking, indication expansion and pipeline prioritization through strategic collaborations with pharmaceutical and biotech partners.

AgenT is a precision diagnostics company dedicated to transforming the prediction and monitoring of neurodegenerative diseases, with an initial focus on Alzheimer’s disease. Built on more than a decade of research, AgenT has developed a strong scientific and technological foundation combining patented biomarkers, proprietary targeted mass spectrometry methods, and AI-based software. This approach enables the company to generate highly specific, clinically relevant insights from blood samples and to address a major unmet need in brain health: earlier, more scalable, and less invasive detection.

AgenT’s proprietary platform is designed to monitor key biological pathways involved in age-related diseases and to support multiple applications ranging from diagnostics and companion diagnostics to therapeutic target discovery. The company also benefits from a unique proprietary database built from more than 5,000 retrospective plasma samples collected across the US, Europe, and Australia, enriched with longitudinal clinical follow-up data. Through this integrated platform and data strategy, AgenT is positioning itself as a next-generation player in precision medicine for neurodegenerative diseases, with a clear path toward clinical validation, commercial deployment, and strategic partnerships in both healthcare and life sciences.

AgenT’s innovative solutions are built around HORIZON™, a proprietary multiomic platform designed to predict and monitor neurodegenerative diseases through a simple blood sample. HORIZON™ combines patented biomarkers, targeted mass spectrometry, and AI-based software, and can monitor 8 key biological pathways through 85 biomarkers. Its first applications, B-HEALED™ and B-AHEAD™, are blood-based tests designed to predict progression to Alzheimer’s dementia symptoms in cognitively unimpaired and impaired individuals. These products have already shown strong performance in a first multicenter retrospective study involving 632 individuals across the US, Europe, and Australia, with 3x fewer false positives than current tests on the market. AgenT is now advancing these solutions through an ongoing 4,200-participant pivotal clinical validation study.

Theremia is a precision medicine company specialized in neurology and psychiatry. Theremia develops explainable and causal AI models to help biotech and pharma companies de-risk and optimize drug development.

Founded in late 2023, Theremia stems from a simple observation: the current “one size fits all” model—one treatment, at one dose, for all patients—does not work in central nervous system (CNS) disorders. In these highly heterogeneous diseases, more than 60% of patients either do not respond to treatment or experience severe adverse effects, which largely explains high clinical failure rates.

To address this challenge, Theremia has developed a multi-scale AI integrating clinical, phenotypic, and pharmacological data to identify the right treatment for specific patient subpopulations based on their profiles and treatment responses. Leveraging causal inference methods, Theremia models treatment response to generate actionable insights compatible with regulatory decision-making.

Theremia’s platform is structured around three core use cases:
– Target Product Profile optimization: early identification of the most promising indications, endpoints, and patient subpopulations to maximize probability of success.
– Clinical trial design and execution: improved patient selection and construction of external control arms to de-risk Phase II/III trials, while reducing timelines and costs.
– Post-approval optimization and lifecycle extension: personalization of treatment parameters (e.g: dose optimization, PK/PD modeling) for potential repositioning or treatment optimization.

What makes Theremia’s technology unique is the combination of highly robust AI models with large-scale, high-quality data that are continuously enriched over time. Theremia leverages more than 1.5 million longitudinal patient records, combining clinical trial data and real-world evidence from Europe and the United States, together with a knowledge graph of over 9 million drugs and more than 20 million connections.

Theremia’s models and datasets are continuously enriched through collaborations with leading academic institutions and validated in partnership with top-tier hospitals, ensuring strong robustness, clinical relevance, and real-world applicability.

Dillico developed the All-ScaleFlow manufacturing platform, an end-to-end automated continuous production system for m/sa/gRNA-LNP therapeutics with related digital tools and services. This solution enables efficient in silico process development for any mRNA therapeutic, leveraging a Performance Modeling Platform. The continuous production is scale-up-free and can process batches ranging from preclinical or individualized medicine scale to large commercial scale. The All-ScaleFlow is a powerful tool to accelerate the advancement of m/sa/gRNA assets through the pipeline.

WhiteLab Genomics, a pioneer in the accelerated development of genomic medicines, sits at the intersection of artificial intelligence and biology. Founded in 2019 and supported by Y Combinator, the company is establishing itself as a key player in genomic medicine innovation. Its proprietary AI technology enables the analysis of complex biological data and the in silico design of optimized therapeutic candidates, thus reducing development time, costs, and associated risks.

WhiteLab collaborates with major pharmaceutical companies (such as Sanofi), leading academic institutions, and innovative biotech companies. WhiteLab is a member of the prestigious French Tech 2030 program and is part of Bayer Co.Lab in Cambridge (USA).

Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biological Artificial Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM fine-tuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.

AQEMIA is a drug invention company developing novel molecules to address unmet medical needs. Its proprietary QEMI platform combines over a decade of physics-based research with state-of-the-art generative AI, enabling the rapid design of drug candidates without relying on experimental training data.

By leveraging its unique fast physics engine, the company reconciles speed and precision in molecular design, unlocking large-scale exploration of previously inaccessible chemical space. Aqemia’s portfolio spans oncology, immunology and neurology, and includes both wholly owned programs and partnered programs with leading pharmaceutical companies, such as a multi-year, $150M strategic collaboration with Sanofi.

The company’s most advanced preclinical programs are currently undergoing in vivo optimization, demonstrating superior efficacy in animal models.

Headquartered in Paris with an office in London, AQEMIA employs around 70 people and has raised over $100 million since its inception.

NETRI is an innovative industrial TechBio whose mission is to improve human health through the discriminating power of the nervous system. The company offers a Neuron-as-a-Sensor suite (NaaS) to gain insights into the safety and efficacy of clinical or chemical compounds. NETRI focuses on pain quantification and pursues an exploratory pipeline in oncology, immunology, neurological disorders, neurotoxicity and dermatology.

Leveraging the natural capacity of neurons to encode biological interactions into electrical impulses, the NaaS suite features the world-first compartmentalized electrophysiology platform in standard 96-well plate format – NeuroFluidics™ MEA – which acts as a data generation hub for its Digital Signature libraries of tested and reference compounds. To enable the prediction of clinical outcomes, the proprietary suite includes calibrated neuronal cells, organ-on-chip hardware, AI-trained software, digital libraries and methods.

NETRI provides two types of offers:
Standard Microphysiological Systems (MPS)
NETRI’s MPS can be acquired with cells & cell reagents, scaffolds and software for R&D groups interested in:
• 3D ECM Matrix for primary or hiPSC-derived organoids and tumoroids (liver, pancreatic carcinoma, adipose tissues, brain).
• Compartmentalized barrier for innervation and vascularization of 3D hiPSC cell cultures, including multi-organoid systems.
• Compartmentalized electrophysiology for co-culture of 2D and 3D CNS or PNS cells, co-culture of neurons and skin cells and neuromuscular junction.

The Neuron-as-a-Sensor (NaaS) platform includes devices, cells & reagents, software (analytics, Digital Signature generation and access to the Digital Library), and the full NaaS methodology. Among others, this platform can be applied to the following applications:
• Drug-induced peripheral neuropathies, including CIPN, for which NETRI is currently establishing a ring trial with 6 major pharmaceutical companies and a world-leading CRO to assess inter-site reproducibility before regulatory submission of the methodology for this context of use
• General CNS neurotoxicity (pharma)
• Skin model (pruritus)
• Inflammatory pain
• Drug-induced seizure
• ALS (motor only)
• General CNS neurotoxicity (chemicals, pesticides)
• DPN (diabetic peripheral neuropathy)
• Emetic and nausea response

NETRI ultimately aims to license its technology for on-premises deployment for internal decision-making and inclusion in regulatory submissions.